Boston Scientific Welcomes Cathy Smith and Christophe Weber to Its Board of Directors

Boston Scientific Welcomes New Board Members

Boston Scientific Corporation, a leader in medical technology, recently announced the election of two new members, Cathy Smith and Christophe Weber, to its Board of Directors. Their appointments, effective February 18, 2026, follow the planned retirements of John Sununu and Yoshiaki Fujimori.

Cathy Smith brings a wealth of experience to the board, particularly in finance and corporate strategy. Currently serving as the Chief Financial Officer for Starbucks, she has held similar positions at prestigious organizations such as Nordstrom and Walmart. Over the years, her leadership has been instrumental in navigating complex companies through periods of substantial growth. Smith holds an MBA from the University of Southern California and an undergraduate degree in business economics from the University of California, Santa Barbara. Her extensive experience in financial management aligns well with Boston Scientific's ongoing focus on sustainable growth and innovation.

Christophe Weber, who has been at the helm of Takeda Pharmaceutical since April 2015, adds significant pharmaceutical industry expertise to the board. With a career that started at GlaxoSmithKline, Weber has led major transformations that emphasize patient and customer-centric approaches. He is set to retire from his role at Takeda in June 2026, but his leadership experience will be a valuable asset to Boston Scientific. Weber earned his doctorate in pharmacy from Université de Lyon and has a master’s degree in accounting and finance, showcasing his diverse skill set that complements Smith’s financial acumen.

Mike Mahoney, the Chairman and CEO of Boston Scientific, expressed his enthusiasm regarding the new board members, stating that both Smith and Weber’s backgrounds will support the company in its ongoing mission to innovate and enhance patient care globally. Mahoney acknowledged their impressive track records, affirming that their strategic insights will greatly assist in driving Boston Scientific's future endeavors.

The transition in the board comes as Boston Scientific seeks to maintain its reputation as a frontrunner in medical technology, especially as it adapts to the evolving healthcare landscape. The company has been committed to delivering high-quality medical solutions that meet the diverse needs of patients worldwide, focusing on cardiovascular, neurological, and other critical health areas.

As Boston Scientific moves forward, the addition of Smith and Weber is poised to strengthen governance and enrich the company’s strategic direction. Stakeholders can look forward to continued advancements in medical technologies that not only improve health outcomes but also contribute to cost-effective care.

In summary, the elections of Cathy Smith and Christophe Weber represent a significant move for Boston Scientific as it fortifies its leadership and reinforces its commitment to innovation and patient-centered care. Both executives are expected to bring comprehensive and insightful perspectives that will guide the company through its next stages of growth and transformation.

For more information on Boston Scientific and its latest developments, visit Boston Scientific's Website.